Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 91
Filter
1.
J Endovasc Ther ; 29(5): 678-691, 2022 10.
Article in English | MEDLINE | ID: mdl-34955053

ABSTRACT

BACKGROUND: Carotid plaque morphology plays an important role in determining outcome of carotid artery stenting (CAS). Intravascular ultrasound (IVUS) and its extension VH (Virtual Histology)-IVUS evaluate plaque characteristics in real time and guide decision making during stenting. To date, there is no consensus about indications of IVUS and its validated methods. This systematic review and meta-analysis aims to evaluate the clinical utility of IVUS in carotid artery interventions (CAS) and develop a future consensus for research and practice parameters. METHODS: A systematic review and meta-analysis was performed of the English literature articles published till February 2021. Studies reporting on IVUS parameters and findings and also its performance compared with other imaging modalities were included in review. Pooled prevalence with 95% confidence intervals (CI) was calculated. The statistical analysis was conducted in R version 3.6.2. RESULTS: A total of 2015 patients from 29 studies were included. Proportional meta-analysis was performed on 1566 patients from 11 studies. In 9 studies, stroke/transient ischemic attack (TIA) had a pooled prevalence of 4% (95% CI 3%-5%) while asymptomatic stroke had a pooled prevalence of 46% (95% CI 31%-62%) in 4 studies following IVUS. Two studies reported that IVUS detected more plaque protrusion compared with angiography (n=33/396 vs 11/396). IVUS led to stent type or size change in 8 of 48 cases which were missed on angiography in 3 other studies. Concordance between VH-IVUS and true histology was good at 80% to 85% reported in 2 studies. CONCLUSIONS: This systematic review and meta-analysis showed, though IVUS fared better to computed tomography (CT)/magnetic resonance (MR) angiography for better stent selection during CAS, with low to moderate risk of bias in the studies included. However, large scale, preferably randomized controlled studies are needed to predict its role in determining clinical outcome.


Subject(s)
Carotid Stenosis , Plaque, Atherosclerotic , Stroke , Carotid Arteries/diagnostic imaging , Carotid Stenosis/diagnostic imaging , Carotid Stenosis/therapy , Humans , Magnetic Resonance Angiography , Plaque, Atherosclerotic/pathology , Predictive Value of Tests , Stents , Stroke/diagnostic imaging , Stroke/etiology , Treatment Outcome , Ultrasonography, Interventional
2.
Nat Commun ; 9(1): 2250, 2018 06 08.
Article in English | MEDLINE | ID: mdl-29884780

ABSTRACT

Treatments that stimulate neuronal excitability enhance motor performance after stroke. cAMP-response-element binding protein (CREB) is a transcription factor that plays a key role in neuronal excitability. Increasing the levels of CREB with a viral vector in a small pool of motor neurons enhances motor recovery after stroke, while blocking CREB signaling prevents stroke recovery. Silencing CREB-transfected neurons in the peri-infarct region with the hM4Di-DREADD blocks motor recovery. Reversing this inhibition allows recovery to continue, demonstrating that by manipulating the activity of CREB-transfected neurons it is possible to turn off and on stroke recovery. CREB transfection enhances remapping of injured somatosensory and motor circuits, and induces the formation of new connections within these circuits. CREB is a central molecular node in the circuit responses after stroke that lead to recovery from motor deficits.


Subject(s)
Cyclic AMP Response Element-Binding Protein/metabolism , Motor Cortex/physiopathology , Motor Neurons/physiology , Neuronal Plasticity/physiology , Recovery of Function/physiology , Stroke/physiopathology , Animals , Brain Mapping , Cyclic AMP Response Element-Binding Protein/genetics , Gene Expression Profiling , Male , Mice, Inbred C57BL , Motor Cortex/metabolism , Motor Neurons/metabolism , Neuronal Plasticity/genetics , Patch-Clamp Techniques , Stroke/genetics
3.
Clin Otolaryngol ; 42(2): 252-262, 2017 Apr.
Article in English | MEDLINE | ID: mdl-27390311

ABSTRACT

OBJECTIVE: Isopeptide bonds form cross-links between constituent proteins in the horny layer of the epidermis. Corneodesmosin (CDSN) is a major component of corneodesmosomes, which bind corneocytes together. Both play important roles in maintaining epidermal barrier functions. In the present study, we investigated the expressions of isopeptide bonds, CDSN, and related enzymes in middle ear cholesteatoma in comparison with the skin. DESIGN: Prospective case series of patients with middle ear cholesteatoma. SETTING: Tertiary medical institute. PARTICIPANTS: Cholesteatoma and normal postauricular skin were collected from patients with acquired middle ear cholesteatoma during tympanomastoidectomy. MAIN OUTCOME MEASURES: Expression of e-(g-glutamyl)lysine isopeptide bonds was examined by immunohistochemistry; Expressions of transglutaminase (TGase)1, TGase2, TGase3, and TGase5 by immunohistochemistry and quantitative RT-PCR (qRT-PCR); expression of CDSN by immunohistochemistry, qRT-PCR, and Western blot; and expressions of tissue kallikrein-related peptidase (KLK)5, KLK7, KLK14, and serine peptidase inhibitor Kazal type 5 (SPINK5) by qRT-PCR. RESULTS: TGase2 was higher (P=0.0046) and TGase5 was lower (P=0.0008) in cholesteatoma than in the postauricular skin. Immunoreactivity for isopeptide bonds was localized in the granular and horny layers, and was not different between the two tissues. Immunoreactivity for CDSN was localized in the granular layer, and was lower in cholesteatoma than in the skin (P=0.0090). Western blot and qRT-PCR confirmed that the expression of CDSN was lower in cholesteatoma than in the skin. Expressions of KLK5, KLK7, KLK14, or SPINK5 were not different between the two tissues. CONCLUSIONS: These results indicate that the production of CDSN is likely to be suppressed in cholesteatoma, which would account, at least in part, for the mechanical fragility and increased permeability of the cholesteatoma epithelium.


Subject(s)
Glycoproteins/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Biomarkers/metabolism , Blotting, Western , Child , Cholesteatoma, Middle Ear/metabolism , Female , Humans , Immunohistochemistry , Intercellular Signaling Peptides and Proteins , Male , Middle Aged , Peptides/metabolism , Prospective Studies , Real-Time Polymerase Chain Reaction , Serine Peptidase Inhibitor Kazal-Type 5/metabolism , Tissue Kallikreins/metabolism , Transglutaminases/metabolism
4.
Case Rep Oncol ; 5(1): 173-80, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22666209

ABSTRACT

The aim of this study was to assess the clinical characteristics and outcome of patients with either primary peritoneal carcinoma (PPC) or ovarian serous carcinoma (OSC) treated with paclitaxel plus carboplatin chemotherapy. We retrospectively identified 22 PPC patients and 55 stage III-IV OSC patients treated between 2002 and 2007. After exploratory laparotomy, all patients received paclitaxel and carboplatin every 3 weeks, with the goal of optimal cytoreduction. There were no statistically significant differences between the PPC and OSC groups with regard to tumor stage, residual tumor after debulking surgery (initial or interval), serum cancer antigen (CA) 125 levels at diagnosis, and completion of first-line chemotherapy. The progression-free survival (PFS) durations were 12.7 months (95% CI, 6.3-18.5) in the patients with PPC and 15.9 months (95% CI, 13.3-18.5) in those with OSC (p = 0.016). However, the median survival durations were 26.5 months (95% CI, 14.6-38.3) in the patients with PPC and 38 months (95% CI, 23.8-53.8) in those with OSC (p = 0.188). Survival was longer for all patients whose CA125 levels normalized to 26 U/ml during and after treatment. Overall survival (OS) of the patients with PPC was similar to that of the patients with OSC, suggesting that management for advanced-stage OSC would be similar to that for PPC. The combination of optimal debulking with paclitaxel plus carboplatin chemotherapy may offer patients the most effective treatment. The CA125 nadir after cytoreductive surgery can be considered a prognostic factor for OS and PFS in patients with PPC.

5.
Placenta ; 33(7): 540-7, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22538230

ABSTRACT

OBJECTIVES: The antiphospholipid syndrome (APS) is characterized by the presence of circulating antiphospholipid antibodies (aPLs), is a leading cause for thromboembolic events, repeated miscarriage, fetal loss and is a major risk factor for fetal growth restriction (FGR) and preeclampsia. In human, anti-ß2 glycoprotein I (aß2GPI) antibody is one of the aPLs and considered to be a specific and important marker for APS. However, pathophysiological changes induced by aß2GPI antibodies in FGR are largely unknown. METHODS: In the present study, we developed a murine FGR model induced by multiple injections of WBCAL-1, a well-characterized mouse aß2GPI monoclonal antibody. RESULTS: Administration of WBCAL-1, but not the isotype control antibody and saline, into pregnant mice specifically decreased the size of fetuses and placentas without affecting the number of delivered pups. Also, a significant increase in urinary albumin and electron microscopic changes, such as splitting layers of basal membranes in the placental labyrinth and rearrangement of pores in glomerular endothelial cells, were observed in WBCAL-1 treated mice. WBCAL-1 injection did not induce any changes in blood pressure and typical parameters of blood thromboembolic symptoms. Furthermore, FcRγ deficiency protected the fetuses from aß2GPI antibody-induced injuries. CONCLUSIONS: Our present findings suggest that proteinuria is a symptom associated with APS-related FGR with placental and renal tissue injuries, and that FcRγ might be a molecular target for prevention of aß2GPI antibody-mediated obstetrical pathologies.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Fetal Growth Retardation/immunology , Receptors, IgG/physiology , beta 2-Glycoprotein I/immunology , Animals , Antibodies, Antiphospholipid/immunology , Antiphospholipid Syndrome/immunology , Antiphospholipid Syndrome/urine , Disease Models, Animal , Female , Fetal Growth Retardation/prevention & control , Fetal Growth Retardation/urine , Mice , Mice, Inbred BALB C , Mice, Knockout , Mice, Nude , Microscopy, Electron , Placenta/immunology , Placenta/pathology , Pregnancy , Proteinuria , Receptors, IgG/deficiency
6.
Eur J Cancer Care (Engl) ; 21(4): 436-41, 2012 Jul.
Article in English | MEDLINE | ID: mdl-21883567

ABSTRACT

Chemotherapy-induced nausea and vomiting (CINV) and nephrotoxicity are adverse events induced by cisplatin administration. These effects can be reduced by treatment regimens with low-dose cisplatin, but high-dose cisplatin is still used. In Japan, high-dose cisplatin is usually administered in an inpatient setting to permit management of CINV. However, with use of new-generation antiemetic agents such as aprepitant, CINV and nephrotoxicity are controllable in an outpatient setting. Here, we discuss issues related to the management of high-dose cisplatin administration in outpatients. Grade 2 or worse CINV induced by high-dose cisplatin occurs in more than 40% of patients without treatment with aprepitant, but is controllable by administration of a 5-HT3 receptor antagonist, steroids and aprepitant. Moreover, prevention of CINV using these drugs is cost-effective, since outpatient settings have advantages with regard to health economics and patient quality of life. These findings suggest that shifting high-dose cisplatin administration to the outpatient setting may be achieved with co-administration of aprepitant. Available facilities and the status of the patient should be considered when selecting whether an outpatient setting is suitable for administration of cisplatin, but the use of aprepitant and adequate oral hydration should allow use of cisplatin in this setting.


Subject(s)
Antiemetics/therapeutic use , Antineoplastic Agents/administration & dosage , Cisplatin/administration & dosage , Kidney/drug effects , Morpholines/therapeutic use , Nausea/prevention & control , Vomiting/prevention & control , Antineoplastic Agents/adverse effects , Aprepitant , Cisplatin/adverse effects , Fluid Therapy/methods , Humans , Kidney Diseases/chemically induced , Kidney Diseases/prevention & control , Nausea/chemically induced , Neoplasms/complications , Neoplasms/drug therapy , Vomiting/chemically induced
8.
Eur J Gynaecol Oncol ; 31(1): 37-43, 2010.
Article in English | MEDLINE | ID: mdl-20349779

ABSTRACT

OBJECTIVE: To determine the clinical characteristics of patients (young women) with cervical carcinoma aged less than 35 years. METHODS: Data from patients who were treated for cervical carcinomas from 1990 to 2000 in the Kinki District were retrospectively investigated for clinical stage, histologic type, treatment procedure and prognosis. RESULTS: Of a total of 4,975 cases, 441 patients were aged less than 35 years old. The incidence of cervical carcinoma in these women was 7.9% from 1990 to 1995, 9.1% from 1996 to 2000, and 9.5% from 2001 to 2005. FIGO Stage I included 374 cases, followed by, 49 in Stage II, 11 in Stage III, and seven in Stage IV. Squamous cell carcinoma incidence was 80.7% and non-squamous cell carcinoma incidence was 19.3%. Several types of surgery were performed in patients with Stage I and II, while patients with Stage III and IV were treated with radiotherapy and/or chemotherapy without any type of surgery. In patients who underwent lymphadenectomy, 21.1% cases had nodal involvement. The 5-year survival rate was 95% for Stage I disease, 73% for Stage II, 68% for Stage III, and 19% for Stage IV. CONCLUSION: The incidence of cervical carcinoma in young women slightly increased from 1990 to 2005. The prognosis of cervical carcinoma tends to be better in young women than in older patients, especially in Stage III disease.


Subject(s)
Uterine Cervical Neoplasms/therapy , Adenocarcinoma/epidemiology , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Adenocarcinoma/therapy , Adult , Age Factors , Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/therapy , Female , Humans , Incidence , Japan/epidemiology , Lymphatic Metastasis , Prognosis , Survival Rate , Uterine Cervical Neoplasms/epidemiology , Uterine Cervical Neoplasms/mortality , Uterine Cervical Neoplasms/pathology
9.
Int J Gynecol Cancer ; 18(3): 414-20, 2008.
Article in English | MEDLINE | ID: mdl-17645503

ABSTRACT

Ovarian cancer is common in women from developed countries. We designed a prospective randomized controlled trial of ovarian cancer screening to establish an improved strategy for the early detection of cancers. Asymptomatic postmenopausal women were randomly assigned between 1985 and 1999 to either an intervention group (n = 41,688) or a control group (n = 40,799) in a ratio of 1:1, with follow-up of mean 9.2 years, in Shizuoka district, Japan. The original intention was to offer women in the intervention group annual screens by gynecological examination (sequential pelvic ultrasound [US] and serum CA125 test). Women with abnormal US findings and/or raised CA125 values were referred for surgical investigation by a gynecological oncologist. In December 2002, the code was broken and the Shizuoka Cohort Study of Ovarian Cancer Screening and Shizuoka Cancer Registry were searched to determine both malignant and nonmalignant diagnoses. Twenty-seven cancers were detected in the 41,688-screened women. Eight more cancers were diagnosed outside the screening program. Detection rates of ovarian cancer were 0.31 per 1000 at the prevalent screen and 0.38-0.74 per 1000 at subsequent screens; they increased with successive screening rounds. Among the 40,779 control women, 32 women developed ovarian cancer. The proportion of stage I ovarian cancer was higher in the screened group (63%) than in the control group (38%), which did not reach statistical significance (P = 0.2285). This is to our knowledge the first prospective randomized report of the ovarian cancer screening. The rise in the detection of early-stage ovarian cancer in asymptomatic postmenopausal women is not significant, but future decisions on screening policy should be informed by further follow-up from this trial.


Subject(s)
CA-125 Antigen/blood , Endosonography , Mass Screening/methods , Ovarian Neoplasms/diagnosis , Age Distribution , Aged , Chi-Square Distribution , Enzyme-Linked Immunosorbent Assay , Female , Humans , Incidence , Japan/epidemiology , Middle Aged , Odds Ratio , Ovarian Neoplasms/epidemiology , Postmenopause , Primary Prevention/methods , Prospective Studies , Risk Assessment , Sensitivity and Specificity , Statistics, Nonparametric
10.
Int J Gynaecol Obstet ; 99(2): 95-9, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17643440

ABSTRACT

BACKGROUND: Little is known about the natural history of ovarian cancer with respect to the change of serum CA125 level. METHODS: The Shizuoka Cohort Study on Ovarian Cancer Screening (SCSOCS) Trial contains approximately 100,000 data on serum tumor marker CA125 prospectively obtained from more than 70,000 women. We reviewed the clinical charts and collected serum samples 2 months to 9.4 years prior to the surgery were available. RESULTS: In 396 (95%) of the 419 patients with ovarian cancer, one serum sample was present before the diagnosis (mean, 4.1 years). The change of CA125 level before the diagnosis of ovarian cancer could be clearly separated into two groups according to the length of the following intervals: 47% (107/228) of patients with non-serous-type ovarian cancers develop secondarily from slightly elevated CA125 level (35

Subject(s)
CA-125 Antigen/blood , Ovarian Neoplasms/blood , Aged , Aged, 80 and over , Disease Progression , Female , Humans , Middle Aged , Ovarian Neoplasms/diagnostic imaging , Predictive Value of Tests , Retrospective Studies , Time Factors , Ultrasonography
11.
Minerva Cardioangiol ; 55(2): 199-211, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17342038

ABSTRACT

Despite a marked reduction in restenosis and the need for repeat revascularization procedures with the use of drug-eluting stents (DES), the risk for stent thrombosis remains of serious concern. Although the safety profiles of DES dose not seem to differ from those of bare metal stent (BMS) in the acute and subacute phases following coronary intervention, recent data suggest a potential increase of thrombotic events late after DES deployment. The main factors associated with late stent thrombosis remain elusive. Delayed re-endothelialization, hypersensitivity reaction, technical and mechanical factors and hypercoagulability have all been proposed as contributing factors. It is unlikely that any of these variables alone can cause stent thrombosis, as the incidence of each factor is much higher than the currently known rates of DES thrombosis. Further, temporal appearances of the thrombotic events represent a challenge to our understanding of re-endothelialization, as one would expect that endothelial coverage would be higher in the later phases after treatment. New expanded definitions of stent thrombosis, which also include events secondary to repeat revascularization, have been proposed to provide a better comparative endpoint between BMS and DES. Such clinical attempt to characterize stent thrombosis is valuable, but does not provide much insight into the pathophysiology and intrinsic thrombotic risk of each device. A true progress in this field will only be possible after we improve our understanding of the patho-physiology of very late stent thromboses, which may differ from events occurring earlier after treatment. The incidence of stent thrombosis remains rare, but its potential catastrophic consequences should remind clinicians and scientists to make every effort to develop strategies and technologies for its prevention. The topic of stent thrombosis in the era of DES will be reviewed in this article.


Subject(s)
Angioplasty, Balloon, Coronary/adverse effects , Coronary Artery Disease/therapy , Coronary Stenosis/therapy , Coronary Thrombosis/etiology , Coronary Thrombosis/prevention & control , Stents , Coronary Restenosis/prevention & control , Coronary Thrombosis/physiopathology , Drug Delivery Systems , Drug Therapy, Combination , Humans , Immunosuppressive Agents/therapeutic use , Incidence , Myocardial Infarction/etiology , Platelet Aggregation Inhibitors/therapeutic use , Prosthesis Design , Risk Factors , Stents/adverse effects , Treatment Outcome
12.
Minerva Cardioangiol ; 55(1): 57-71, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17287681

ABSTRACT

Bifurcation coronary artery disease is a frequent problem faced by interventional cardiologists and it affects approximately 15-20% of patients undergoing percutaneous coronary intervention (PCI). The application of drug-eluting stents (DES) technology to prevent restenosis after PCI represents one of the success stories in cardiology, but DES have not resolved the bifurcation PCI challenge. Bifurcation PCI remains associated with higher procedural failure and worse outcomes compared with PCI of non-bifurcated lesions even in DES era. A dependable strategy for PCI of bifurcation lesions has yet to be established, which is likely due to the paucity of studies evaluating the anatomical intricacies of the bifurcation as well as the lack of large scale randomized therapeutic trials. Further, bifurcation has many anatomical variants and it is unlike that one technique will fit all. Currently, we are left with the option of a tailor-made strategy for each patient and bifurcation anatomy and make the most of the limited evidence available to support our therapeutic decisions. In this review, we attempted to describe the current understanding of bifurcation anatomy and corresponding PCI strategies.


Subject(s)
Angioplasty, Balloon, Coronary , Coronary Artery Disease/therapy , Coronary Restenosis/prevention & control , Stents , Coronary Artery Disease/pathology , Humans , Risk Factors , Treatment Outcome
13.
Minerva Cardioangiol ; 55(1): 105-14, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17287685

ABSTRACT

Cardiac magnetic resonance imaging (cMRI) is a promising non-invasive technique to assess the presence of coronary artery disease (CAD), which is free of ionizing radiation and iodine contrast. cMRI can detect CAD by angiographic methods or indirectly by perfusion stress techniques. While coronary angiography by cMRI remains limited to research protocols, stress perfusion cMRI is currently being applied worldwide in the clinical setting. Studies have shown good correlation between adenosine-induced stress myocardial perfusion cMRI and single-photon-emission computed tomography or positron emission tomography to detect CAD. Quantitative methods to analyze cMRI perfusion data have been developed in an attempt to provide a more objective imaging interpretation. Standardization of such quantitative methods, with minimal operator dependency, would be useful for clinical and research applications. Myocardial perfusion reserve (MPR), calculated using Fermi deconvolution technique, has been compared with well established anatomical and physiological CAD detection techniques. MPR appears to be the most accurate quantitative index to detect anatomical and hemodynamically significant CAD. Beyond physiological assessment of CAD, cMRI provides information regarding regional and global left ventricular function and morphology, myocardial infarction size, transmurality and viability. Such comprehensive information would require the performance of multiple tests if other modalities were used. This article describes current applications of cMRI for evaluation of patients with CAD.


Subject(s)
Coronary Artery Disease/diagnosis , Magnetic Resonance Imaging , Coronary Angiography , Humans , Magnetic Resonance Imaging/methods , Myocardial Reperfusion , Sensitivity and Specificity
14.
Int J Gynecol Cancer ; 16(4): 1545-51, 2006.
Article in English | MEDLINE | ID: mdl-16884363

ABSTRACT

The purpose of this study was to determine whether Akt and mammalian target of rapamycin (mTOR), downstream targets of phosphatidylinositol 3-kinase, are activated in endometriosis and ovarian cancer specimens. We measured total and phosphorylated levels of Akt and mTOR from 17 frozen ovarian cancers and 15 benign endometriosis specimens (nine from premenopausal women and six from postmenopausal women) by quantitation of signals from western blots using antibodies against these proteins. Elevated phospho-Akt was detected in ovarian cancer versus endometriosis specimens from premenopausal women and endometriosis specimens from postmenopausal women (2.3 +/- 0.45 versus 0.10 +/- 0.06 and 0.17 +/- 0.11; P < 0.05) when the western blot signal of activated kinase was normalized to total kinase levels. Elevated phospho-mTOR was detected in ovarian cancer and postmenopausal endometriosis versus premenopausal endometriosis (0.52 +/- 0.19 and 0.46 +/- 0.29 versus 0.13 +/- 0.08; P < 0.05). Expression of total kinases (normalized to beta-actin) was higher in carcinoma versus endometriosis specimens. Elevation of the active mTOR was specifically detected in postmenopausal endometriosis.


Subject(s)
Endometriosis/metabolism , Ovarian Neoplasms/metabolism , Postmenopause/metabolism , Protein Kinases/metabolism , Adult , Aged , Aged, 80 and over , Blotting, Western , Endometriosis/pathology , Female , Humans , Middle Aged , Ovarian Neoplasms/pathology , Phosphatidylinositol 3-Kinases/metabolism , Phosphorylation , Proto-Oncogene Proteins c-akt/metabolism , Retrospective Studies , Signal Transduction , TOR Serine-Threonine Kinases
15.
Aliment Pharmacol Ther ; 16 Suppl 2: 180-6, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11966539

ABSTRACT

BACKGROUND: Helicobacter pylori infection is involved in the formation of chronic peptic ulcer. However, a previously reported hypothesis concerning the involvement of central autonomic nervous disorder in this condition cannot be ruled out. AIM: To use spectrum analysis of heart rate viability to examine autonomic nervous activity before and after H. pylori eradication. METHODS: Twenty patients with chronic duodenal ulcer (duodenal ulcer group) and 20 age-matched normal adults (N group). In both groups, 24-h Holter electrocardiograms (ECGs) were recorded and spectrum analysis of heartrate variability was performed. In the duodenal ulcer group, Holter ECG was recorded before and after H. pylori eradication. RESULTS: In the N group, analysis of heart rate variability showed that high frequency (HF) power, an index of parasympathetic activity, was high at night, while the low frequency (LF)/HF ratio, an index of sympathetic function, was high during the daytime. In the duodenal ulcer group, HF power was higher at night than during the daytime, showing a similar pattern to the N group, but the power value was higher than in the N group (P < 0.05). In the duodenal ulcer group, LF/HF at night was significantly higher than that of the N group. In addition, in the duodenal ulcer group, autonomic activity after H. pylori eradication did not differ significantly from that before H. pylori eradication. CONCLUSIONS: In patients with chronic peptic ulcer, both sympatheticotonia and parasympatheticotonia may occur at night, and this abnormality in autonomic nervous activity may cause increased gastric acid secretion and gastric mucosal vasoconstriction. Abnormalities in autonomic activity persist even after H. pylori eradication, suggesting that they may be an independent risk factor in the formation of chronic peptic ulcer in addition to H. pylori infection.


Subject(s)
Autonomic Nervous System Diseases/complications , Duodenal Ulcer/etiology , Helicobacter Infections/complications , Helicobacter pylori/isolation & purification , Autonomic Nervous System Diseases/physiopathology , Duodenal Ulcer/physiopathology , Female , Heart Rate/physiology , Helicobacter Infections/drug therapy , Helicobacter Infections/microbiology , Helicobacter Infections/physiopathology , Helicobacter pylori/drug effects , Humans , Male , Middle Aged
16.
J Cardiol ; 38(5): 239-44, 2001 Nov.
Article in Japanese | MEDLINE | ID: mdl-11729723

ABSTRACT

OBJECTIVES: The strategy for post coronary artery bypass grafting (CABG) was investigated in patients with graft stenosis. METHODS: The study included 123 post-CABG patients with graft stenosis. The patients were divided into three groups according to target vessels; saphenous vein graft (SVG; n = 72), internal mammary artery (IMA; n = 21) and native coronary artery (n = 30). Furthermore, SVG lesions were divided into proximal anastomosis (n = 23), body (n = 40) and distal anastomosis (n = 9). The procedural success rate and late patency rate were compared between the three groups. Furthermore, the relationships between pre percutaneous transluminal coronary angioplasty (PTCA) percentage diameter stenosis, procedural success rate and late patency rate were evaluated. RESULTS: Procedural success rate was similar in the three groups, but late patency rate was higher in the IMA group. Procedural success rate and late patency rate were significantly lower in proximal anastomoses compared to other sites of SVG stenoses, IMA group and native coronary artery group (p < 0.05). Totally occluded native coronary artery lesions had a high procedural success rate compared with occluded IMA and SVG lesions, but the late patency rate was not higher. Procedural success rate showed no significant difference for 75-99% stenotic lesions, but the late patency rate was significantly higher in the IMA group (p < 0.05). Patients in the stenting group had a greater late patency rate compared with the balloon angioplasty group. There was no significant difference in late patency rate between the IMA group and SVG group. CONCLUSIONS: Late patency rate of the IMA is higher than that of the native coronary artery. SVG with proximal anastomosis and severe stenosis shows a significantly lower late patency rate than the native coronary artery. Therefore, PTCA should be considered for the native coronary artery in the absence of chronic total occlusion.


Subject(s)
Angioplasty, Balloon, Coronary , Coronary Artery Bypass , Coronary Restenosis/therapy , Myocardial Revascularization , Aged , Female , Humans , Male , Middle Aged , Saphenous Vein , Stents , Vascular Patency
17.
Biotechniques ; 31(4): 948-50, 952-3, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11680726

ABSTRACT

The Rapid Translation System (RTS 500) (Roche Molecular Biochemicals) is a high-yield protein expression system that utilizes an enhanced E. coli lysate for an in vitro transcription/translation reaction. In contrast to conventional transcription/translation, this system allows protein expression to continue for more than 24 h. We demonstrated the utility of the RTS 500 by expressing different soluble and active proteins that generally pose problems in cell-based expression systems. We first expressed GFP-lunasin, a fusion protein that, because of its toxicity, has been impossible to produce in whole cells. The second protein we expressed, human interleukin-2 (IL-2), is generally difficult to produce, either as the native molecule or as a GSTfusion protein, in a soluble form in bacteria. Finally, we demonstrated the capacity of the RTS 500 to co-express proteins, by the simultaneous production of GFP and CAT in a single reaction. This new technology appears to be particularly usefulfor the convenient production of preparative amounts (100-900 microg) of proteins that are toxic or insoluble in cell-based systems.


Subject(s)
Biotechnology/instrumentation , Protein Biosynthesis , Proteins/genetics , Transcription, Genetic , 3T3 Cells , Animals , Chloramphenicol O-Acetyltransferase/biosynthesis , Chloramphenicol O-Acetyltransferase/genetics , Chloramphenicol O-Acetyltransferase/isolation & purification , Cloning, Molecular , Escherichia coli/genetics , Gene Expression , Green Fluorescent Proteins , In Vitro Techniques , Interleukin-2/biosynthesis , Interleukin-2/genetics , Interleukin-2/isolation & purification , Killer Cells, Lymphokine-Activated/immunology , Luminescent Proteins/biosynthesis , Luminescent Proteins/genetics , Luminescent Proteins/isolation & purification , Mice , Proteins/isolation & purification , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/isolation & purification
18.
J Cardiol ; 37(3): 151-6, 2001 Mar.
Article in Japanese | MEDLINE | ID: mdl-11281055

ABSTRACT

OBJECTIVES: The rates of cardiac events and coronary revascularization were evaluated in patients with significant coronary stenosis of more than 75% by the American Heart Association (AHA) classification but no ischemic evidence by exercise myocardial perfusion scintigraphy. METHODS: Subjects were 171 patients (113 males, 58 females, mean age 66 +/- 9 years) undergoing coronary angiography and without scintigraphic evidence of myocardial ischemia. They were divided into two groups according to the severity of coronary artery stenosis based on AHA classification. Group A was composed of 139 patients with more than 75% stenosis (101 patients with 75% stenosis and 38 patients with more than 90% stenosis), and Group B was composed of 32 patients with 50% stenosis. Cardiac events including angina pectoris (n = 63), myocardial infarction (n = 1), heart failure (n = 2) and cardiac death (n = 0), coronary revascularization and predictive factors were evaluated during follow-up of 34 +/- 21 months. Furthermore, the interval between coronary revascularization and exercise myocardial perfusion scintigraphy was estimated. RESULTS: The rates of cardiac events (45%) and coronary revascularization (29%) in Group A were significantly higher than the rate of cardiac events (9%, p < 0.05) and coronary revascularization (6%, p < 0.05) in Group B. Only percentage stenosis and the number of diseased vessels affected the rates of cardiac event and coronary revascularization. CONCLUSIONS: Patients with significant coronary stenosis, but without ischemic evidence by exercise myocardial perfusion scintigraphy, have a relatively high rate of cardiac event and coronary revascularization, especially in patients with severe stenosis or multivessel disease. However, coronary revascularization should not be performed in all patients with significant coronary stenosis.


Subject(s)
Angina Pectoris/diagnostic imaging , Coronary Disease/diagnostic imaging , Coronary Vessels/pathology , Heart/diagnostic imaging , Aged , Coronary Angiography , Coronary Disease/etiology , Coronary Disease/pathology , Female , Humans , Male , Middle Aged , Myocardial Revascularization , Prognosis , Radionuclide Imaging
19.
Cornea ; 20(1): 100-3, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11188990

ABSTRACT

PURPOSE: A web-like retrocorneal membrane (RCM) is an uncommon complication of chronic syphilitic interstitial keratitis. Extracellular matrix components have not yet been defined in this structure, although previous histologic examinations have suggested the presence of collagen. We examined the presence and distribution of extracellular matrix components in a patient with an RCM. METHODS: A specimen of the opaque cornea affected by syphilitic interstitial keratitis with RCM formation was obtained during penetrating keratoplasty in a 62-year-old woman and was evaluated by histology, immunohistochemistry, and scanning electron microscopy (SEM). Antibodies against collagen types I, III, and IV; fibronectin; vimentin; alpha-smooth muscle actin (alpha-SMA); heat shock protein 47 (Hsp 47); proliferating cell nuclear antigen (PCNA); and Ki67 were used. RESULTS: Histologic analysis detected multiple concentric, acellular layers positive for collagen types I, III, and IV. The corneal endothelial cells (CECs) were positive for vimentin, collagen I, fibronectin, and Hsp 47 but not for alpha-SMA. Furthermore, the CECs were negative for PCNA and Ki67, indicating that they were not proliferating. SEM revealed the RCM was covered by CECs with a fibroblastic appearance. CONCLUSION: RCM associated with syphilitic interstitial keratitis contained collagen types I, III, and IV and fibroblast-like CECs. These CECs may secrete the extracellular matrix components found in the RCM. Hsp 47 up-regulation in the CECs may play an important role in RCM formation. These findings provide further insights into the phenotypic modulation of CECs.


Subject(s)
Endothelium, Corneal/ultrastructure , Extracellular Matrix/ultrastructure , Eye Infections, Bacterial , Keratitis/pathology , Syphilis/pathology , Collagen/immunology , Collagen/metabolism , Endothelium, Corneal/metabolism , Extracellular Matrix/metabolism , Eye Infections, Bacterial/metabolism , Eye Infections, Bacterial/microbiology , Eye Infections, Bacterial/pathology , Female , Fluorescent Antibody Technique, Indirect , HSP47 Heat-Shock Proteins , Heat-Shock Proteins/immunology , Heat-Shock Proteins/metabolism , Humans , Keratitis/metabolism , Keratitis/microbiology , Microscopy, Electron, Scanning , Middle Aged , Proliferating Cell Nuclear Antigen/immunology , Proliferating Cell Nuclear Antigen/metabolism , Syphilis/metabolism , Syphilis/microbiology
20.
J Med ; 32(5-6): 333-47, 2001.
Article in English | MEDLINE | ID: mdl-11958279

ABSTRACT

This study is intended to clarify the relationship between occurrence of peptic ulcer disease and dysfunction of the autonomic nervous system. We studied heart rate variability and assessed the circadian rhythm of autonomic nervous function in 20 patients with peptic ulcer (PU group) and 20 age-matched healthy controls (N group) using 24-hour Holter monitoring. Moreover, the relationship between gastric juice secretion and autonomic activity was examined under intravenous injection of insulin or butylscopolamine in adult mongrel dogs. High frequency spectral (HF) power, an indicator of parasympathetic tone, was increased markedly at night in the PU group. Low frequency spectral (LF) power, an indicator of sympathetic tone modified by vagal tone, was higher during the day than at night in the N group, whereas this normal circadian rhythm of LF power disappeared in 11 cases (55%) in the PU group. In addition, the LF power was increased significantly at night (p<0.01) in the PU group. HF power and gastric juice secretion was increased by the administration of insulin. High sympatho-vagal tone at night may result in spasm of gastric arteries and excess secretion of gastric acid in the PU group. These results suggest that the nocturnal acceleration of LF, HF, and LF/HF is related to peptic ulcer diseases.


Subject(s)
Autonomic Nervous System/physiopathology , Heart Rate , Peptic Ulcer/physiopathology , Adult , Aged , Animals , Dogs , Electrocardiography, Ambulatory , Female , Gastric Juice/metabolism , Helicobacter Infections/complications , Helicobacter Infections/physiopathology , Helicobacter pylori , Humans , Male , Middle Aged , Peptic Ulcer/microbiology , Reference Values
SELECTION OF CITATIONS
SEARCH DETAIL
...